Literature DB >> 14600034

1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat.

Alexander Kuhlmann1, Christian S Haas, Marie-Luise Gross, Udo Reulbach, Marc Holzinger, Ute Schwarz, Eberhard Ritz, Kerstin Amann.   

Abstract

1,25(OH)(2)D(3) has antiproliferative effects and promotes cell differentiation. This consideration has provided the rationale for studies in subtotally nephrectomized rats showing that 1,25(OH)(2)D(3) interfered with glomerulosclerosis. The cellular mechanisms involved have remained obscure, however. It was the purpose of the present study to assess glomerular structure and cellular composition in subtotally nephrectomized (SNX) rats treated with nonpharmacological doses of 1,25(OH)(2)D(3). Male Sprague-Dawley rats were sham operated (sham) or underwent SNX under general anesthesia and received either solvent or 1,25(OH)(2)D(3) (3 ng.100 g body wt(-1).day(-1) sc). Blood pressure (BP) and albuminuria were measured. After 16 wk, the remnant renal tissue was perfusion fixed and morphometric and stereological measurements were carried out. The expression of proliferating cellular antigen (PCNA), cyclin-dependent kinase inhibitor p27, Wilms tumor gene (WT1), and desmin, a marker of early podocyte damage, was investigated by immunohistology. BP, serum creatinine, and urinary albumin excretion were significantly higher in SNX than in sham rats. Albuminuria was significantly lower in SNX+1,25(OH)(2)D(3) compared with SNX+solvent rats. Mean glomerular tuft volume was significantly higher in SNX+solvent (2.69 +/- 0.21 gx 10(6) microm(3)) than in sham rats (1.44 +/- 0.17 and 1.28 +/- 0.14 x 10(6) microm(3)); it was significantly (P < 0.05) lower in SNX+1,25(OH)(2)D(3) rats (1.81 +/- 0.16 x 10(6) microm(3)). The main finding was a significantly higher number of podocytes in SNX+1,25(OH)(2)D(3) (88 +/- 9) and sham (98 +/- 17) compared with SNX+solvent rats (81 +/- 8.7). In parallel, the increase in podocyte volume in SNX+solvent rats was abrogated by treatment with 1,25(OH)(2)D(3), and immunohistochemistry revealed less expression of desmin, PCNA, and p27, suggesting less podocyte injury and activation of the cyclin cascade. This study identifies the podocyte as an important target cell for the renoprotective action of 1,25(OH)(2)D(3). This notion is suggested by less evidence of podocyte injury, decreased podocytes loss, and abrogation of podocyte hypertrophy, findings that may also explain less pronounced albuminuria and glomerulosclerosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14600034     DOI: 10.1152/ajprenal.00316.2003

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  75 in total

Review 1.  Nuclear receptors in renal disease.

Authors:  Moshe Levi
Journal:  Biochim Biophys Acta       Date:  2011-04-14

2.  Estimated GFR, albuminuria, and complications of chronic kidney disease.

Authors:  Lesley A Inker; Josef Coresh; Andrew S Levey; Marcello Tonelli; Paul Muntner
Journal:  J Am Soc Nephrol       Date:  2011-09-30       Impact factor: 10.121

3.  Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate.

Authors:  Ian H de Boer; Ronit Katz; Michel Chonchol; Joachim H Ix; Mark J Sarnak; Michael G Shlipak; David S Siscovick; Bryan Kestenbaum
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-11       Impact factor: 8.237

4.  In vitro and in vivo inhibition of mTOR by 1,25-dihydroxyvitamin D3 to improve early diabetic nephropathy via the DDIT4/TSC2/mTOR pathway.

Authors:  Hang Wang; Jianmin Wang; Hua Qu; Huili Wei; Baolan Ji; Zesong Yang; Jing Wu; Qin He; Yuanyuan Luo; Dan Liu; Yang Duan; Fang Liu; Huacong Deng
Journal:  Endocrine       Date:  2016-07-09       Impact factor: 3.633

5.  Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury.

Authors:  Weichun He; Young Sun Kang; Chunsun Dai; Youhua Liu
Journal:  J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 10.121

6.  Therapeutic role and potential mechanisms of active Vitamin D in renal interstitial fibrosis.

Authors:  Xiaoyue Tan; Yingjian Li; Youhua Liu
Journal:  J Steroid Biochem Mol Biol       Date:  2007-01-05       Impact factor: 4.292

7.  Vitamin D and kidney disease.

Authors:  Wisam Al-Badr; Kevin J Martin
Journal:  Clin J Am Soc Nephrol       Date:  2008-05-01       Impact factor: 8.237

Review 8.  Vitamin D and diabetic nephropathy.

Authors:  Yan Chun Li
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

9.  Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria.

Authors:  Yingjian Li; Young Sun Kang; Chunsun Dai; Lawrence P Kiss; Xiaoyan Wen; Youhua Liu
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

10.  Vitamin D status and outcomes after renal transplantation.

Authors:  Frank Bienaimé; Delphine Girard; Dany Anglicheau; Guillaume Canaud; Jean Claude Souberbielle; Henri Kreis; Laure Hélène Noël; Gérard Friedlander; Caroline Elie; Christophe Legendre; Dominique Prié
Journal:  J Am Soc Nephrol       Date:  2013-03-28       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.